SCM
NBIX icon

Sterling Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Sterling Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
3,601
+2,540
+239% +$377K 0.01% 720
2026
Q1 		$140K Sell
1,061
-359
-25% -$47.6K ﹤0.01% 1290
2025
Q4 		$201K Buy
1,420
+429
+43% +$62.1K ﹤0.01% 1313
2025
Q3 		$139K Sell
991
-65
-6% -$8.81K ﹤0.01% 1427
2025
Q2 		$133K Buy
1,056
+722
+216% +$82.8K ﹤0.01% 1317
2025
Q1 		$36.9K Sell
334
-1,278
-79% -$162K ﹤0.01% 1500
2024
Q4 		$220K Sell
1,612
-211
-12% -$26.1K ﹤0.01% 1243
2024
Q3 		$210K Buy
+1,823
New +$250K ﹤0.01% 1253
2018
Q4 		– Sell
-33,227
Closed -$4.08M – 904
2018
Q3 		$4.08M Hold
33,227
– – 0.04% 273
2018
Q2 		$3.26M Hold
33,227
– – 0.03% 301
2018
Q1 		$2.76M Buy
33,227
+16,919
+104% +$1.43M 0.03% 335
2017
Q4 		$1.26M Buy
+16,308
New +$1.11M 0.01% 536
2014
Q2 		– Sell
-18,625
Closed -$300K – 910
2014
Q1 		$300K Buy
+18,625
New +$319K ﹤0.01% 859

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sterling Capital Management's NBIX Position: Q2 2026 in Review

Sterling Capital Management increased its Neurocrine Biosciences (NBIX) stake by 239% in Q2 2026, buying an estimated $377K and bringing the position to 3,601 shares worth $607K. The position accounts for 0.01% of the portfolio, ranked #720.

Sterling Capital Management first reported a position in NBIX in Q1 2014 and has held it in 13 quarters since. The position peaked at $4.08M in Q3 2018. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sterling Capital Management held 3,601 shares of Neurocrine Biosciences worth $607K as of Q2 2026.
  • Sterling Capital Management bought 2,540 Neurocrine Biosciences shares in Q2 2026, an estimated $377K.
  • Neurocrine Biosciences made up 0.01% of Sterling Capital Management's portfolio in Q2 2026, its #720 holding.
  • Sterling Capital Management first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 13 quarters since.
  • Sterling Capital Management's Neurocrine Biosciences position peaked at $4.08M in Q3 2018.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.